CDR-Life develops highly targeted T cell engagers (TCEs) for the treatment of solid cancers and autoimmune diseases. In early clinical development and backed by leading cross-Atlantic investors, our team is committed to bringing life-changing, disease-modifying medicines to patients globally.
Products, services, technology
CDR-Life’s programs include novel targeted T cell engager (TCE) therapies against challenging but clean antigens. The company’s portfolio contains several first-in-class targeted immunotherapies against solid tumors and autoimmune disease.
Cooperation possibilities
Our longstanding partnership with Boehringer Ingelheim (BI) on a molecule in geographic atrophy now in Phase 2, and our new partnership with BI in autoimmune disease demonstrate the potential of our M-gager® platform.
- http://www.cdr-life.com
- +41 44 515 98 98
- Send an email
- Christian Leisner, PhD
Some insights
Helping people live longer and better by bringing new cancer therapies that shrink tumors when nothing else works.
- A world class biotech team
- Developing breakthrough therapies
- Goal of helping people live longer and better
